Trademark Overview
On Monday, October 7, 2024, a trademark application was filed for MAXION with the United States Patent and Trademark Office. The USPTO has given the MAXION trademark a serial number of 79412149. The federal status of this trademark filing is NON-FINAL ACTION COUNTED - NOT MAILED as of Tuesday, April 1, 2025. This trademark is owned by Maxion Therapeutics Limited. The MAXION trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceuticals and pharmaceutical preparations; drugs; antibodies for medical use; pharmaceuticals, drugs and pharmaceutical preparations incorporating antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins; vaccines.
Chemicals for use in industry and science; biochemicals, including polypeptides and antibodies for scientific, laboratory or research purposes; polypeptides and antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel blocking antibodies for scientific, laboratory or research purposes; ion channel blocking antibodies for use in the manufacture of pharmaceuticals and drugs; antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs.
Medical services; medical testing, analysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid.
Scientific and technological services and research and design relating thereto; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; laboratory services relating to the production of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid.
